Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 1.00 |
| ▸ | NPC1 | O15118 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281972 | 0.89 | RAB9A (1.00) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4284337 | 0.88 | RAB9A (0.80) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL14160553 | 0.87 | RAB9A (0.77) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4286756 | 0.83 | RAB9A (0.71) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4283494 | 0.82 | RAB9A (1.00) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4278433 | 0.79 | RAB9A (0.72) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4288327 | 0.78 | RAB9A (1.00) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL15498768 | 0.77 | LMNA (0.66) | RAB9ANPC1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL13947125 | 0.77 | HPGD (0.74) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4288975 | 0.77 | RAB9A (1.00) | RAB9ANPC1KDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| US-20090191183-A1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | SIERRA SCIENCES INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | RAB9A 4044/4885NPC1 2894/4885KDM4E 1668/4885 |
| US-20090191183-A1 | SUBSTITUTED INDOLES | CYSLTR1, LTB4R, LTB4R2 | RAB9A 3532/4885NPC1 744/4885KDM4E 3351/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | RAB9A 4662/4885NPC1 4442/4885KDM4E 541/4885 |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | TERT, TERF2, RNMT | RAB9A 3970/4885NPC1 2996/4885KDM4E 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.